Powering the Immune System to Transform Lives
Our Pipeline
A Deep, Broad Pipeline to Address Unmet Patient Need
Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world.
Hepatitis Delta
tobevibart ± elebsiran
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,75%
Learn more about our therapeutic focus on Hepatitis Delta
Hepatitis B
tobevibart + elebsiran ± PEG-IFN-α
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,75%
Learn more about our therapeutic focus on Hepatitis B
Solid Tumors
VIR-5818 (HER2) ± pembrolizumab
- Treatment Type:
- Treatment
- Phase:
- Phase 1,100%
VIR-5500 (PSMA)
- Treatment Type:
- Treatment
- Phase:
- Phase 1,100%
VIR-5525 (EGFR)
- Treatment Type:
- Treatment
- Phase:
- Pre-clinical,100%
Learn more about our therapeutic focus on Oncology
HIV Cure
Preclinical antibody candidates
- Collaborator:
- Bill & Melinda Gates Foundation
- Treatment Type:
- Treatment
- Phase:
- Pre-clinical,100%
Learn more about our therapeutic focus on HIV
RSV program out-licensed to GSK
HIV: Human Immunodeficiency Virus; RSV: Respiratory Syncytial Virus; PEG-IFN-α: peg-interferon alfa-2a; mAb: monoclonal antibody. Tobevibart incorporates Xencor’s Xtend™ and other Fc technologies.